Investing Focus: Traders Keen on Shares of Dana Incorporated (DAN), AstraZeneca PLC (AZN)

The shares of Dana Incorporated (NYSE:DAN) dropped by -54.78% or -$19.32 from its last recorded high of $35.27 which it attained on January 16 to close at $15.95 per share. Over the past 52 weeks, the shares of Dana Incorporated has been trading as low as $12.65 before witnessing a massive surge by 26.09% or $3.3. This price movement has led to the DAN stock receiving more attention and has become one to watch out for. It dipped by -1.73% on Sunday and this got the market worried. The stock’s beta now stands at 1.78 and when compared to its 200-day moving average and its 50-day moving average, DAN price stands -18.75% below and 10.75% above respectively. Its average daily volatility for this week is 4.16% which is less than the 5.23% recorded over the past month.

Dana Incorporated (DAN) rose 7.55% this week, a trend that has led to both investors and traders taking note of the stock. Over the past one year, the equity price has embarked on a drop that has seen it decline -52.03% and is now up by 17.02% since start of this year. A look at its monthly performance shows that the stock has recorded a 13.85% gain over the past 30 days. Its equity price dipped by -6.23% over the past three months which led to its overall six-month decrease to stand at -23.06%.

Experts from research firms are bullish about the near-term performance of Dana Incorporated with most of them predicting a $19.14 price target on a short-term (12 months) basis. The average price target by the analysts will see a 20% rise in the stock and would lead to DAN’s market cap to surge to $2.82B. The stock has been rated an average 2.3, which roughly stands towards the bearish end of the spectrum. Reuters looked into the 9 analysts that track Dana Incorporated (NYSE:DAN) and find out that 6 of them rated it as a Hold. 3 of the 3 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.

A look at DAN technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 66.75 point. Its trading volume has lost -708636 shares compared to readings over the past three months as it recently exchanged 1301364 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 2010000 shares, and this is 0.65 times the normal volume.

The price of AstraZeneca PLC (NYSE:AZN) currently stands at $36.95 after it went down by $-1.31 or -3.42% and has found a strong support at $36.64 a share. If the AZN price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $36.34 mark would also be bad for the stock as it means that the stock would plunge by 1.65% from its current position. However, if the stock price is able to trade above the resistance point around $37.5, then it could likely surge higher to try and break the upward resistance which stands at $38.05 a share. Its average daily volatility over the past one month stands at 1.75%. The stock has plunged by 0.18% from its 52-weeks high of $36.885 which it reached on Nov. 13, 2018. In general, it is 11.53% above its 52-weeks lowest point which stands at $32.69 and this setback was observed on Jan. 03, 2018.

Analysts have predicted a price target for AstraZeneca PLC (AZN) for 1 year and it stands at an average $40.96/share. This means that it would likely increase by 10.85% from its current position. The current price of the stock has been moving between $36.885 and $37.74. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $26.66. On the other hand, one analyst is super bullish about the price, setting a target as high as $53.79.

The AZN stock Stochastic Oscillator (%D) is at 45.65%, which means that it is currently neutral. The shares P/S ratio stands at 4.47 which compares to the 4 recorded by the industry or the 6.26 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 21.03, which is lower than the 38.25 multiple of 12-month price-earnings (P/E). The company’s earnings have gone down, with a quarterly decrease rate of -13.5% over the past five years.

Analysts view AstraZeneca PLC (NYSE:AZN) as a Buy, with 1.7 consensus rating. Reuters surveyed 6 analysts that follow AZN and found that 1 of those analysts rated the stock as a Hold. The remaining 5 were divided, with 5 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying AstraZeneca PLC (AZN) shares or sell it if they already own it.